Richard M Stone

List of Publications by Citations

267 papers	11,963 citations	46 h-index	107 g-index
279 ext. papers	14,821 ext. citations	5.4 avg, IF	6.05 L-index

#	Paper	IF	Citations
267	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. *New England Journal of Medicine*, **2017**, 377, 454-464	59.2	1067
266	Enasidenib in mutant relapsed or refractory acute myeloid leukemia. *Blood*, **2017**, 130, 722-731	2.2	831
265	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. *New England Journal of Medicine*, **2018**, 378, 2386-2398	59.2	708
264	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA - Journal of the American Medical Association*, **2009**, 301, 2349-61	27.4	612
263	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood*, **2005**, 105, 54-60	2.2	563
262	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. *Cancer Discovery*, **2016**, 6, 1106-1117	24.4	560
261	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood*, **2015**, 125, 1367-76	2.2	497
260	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. *New England Journal of Medicine*, **2018**, 379, 2517-2528	59.2	455
259	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2018**, 36, 2684-2692	2.2	446
258	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood*, **2014**, 124, 2705-12	2.2	411
257	Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. *Journal of Clinical Oncology*, **2010** , 28, 4339-45	2.2	382
256	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. *Blood*, **2011**, 117, 3294-301	2.2	323
255	Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2019**, 381, 432-443	59.2	322
254	NCCN Clinical Practice Guidelines Acute myeloid leukemia. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10, 984-1021	7.3	194
253	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. *Blood*, **2006**, 108, 3477-83	2.2	172
252	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. *Science Translational Medicine*, **2018**, 10,	17.5	165
251	Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, **1999**, 17, 3128-35	2.2	159

250	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. *Cancer Cell*, **2016**, 29, 574-586	24.3	154
249	Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. *Cancer Discovery*, **2014**, 4, 1074-87	24.4	146
248	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. *Cancer Immunology Research*, **2019**, 7, 100-112	12.5	128
247	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. *Cancer Discovery*, **2017**, 7, 156-164	24.4	121
246	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. *Journal of Clinical Oncology*, **2015**, 33, 4167-75	2.2	111
245	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. *Science Translational Medicine*, **2016**, 8, 368ra171	17.5	102
244	SYK is a critical regulator of FLT3 in acute myeloid leukemia. *Cancer Cell*, **2014**, 25, 226-42	24.3	101
243	How I treat mixed-phenotype acute leukemia. *Blood*, **2015**, 125, 2477-85	2.2	96
242	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized	2.2	93
241	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. *Blood*, **2017**, 129, 3175-3183	2.2	88
240	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. *Blood Advances*, **2018**, 2, 444-453	7.8	88
239	Targeting MTHFD2 in acute myeloid leukemia. *Journal of Experimental Medicine*, **2016**, 213, 1285-306	16.6	85
238	A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. *Blood*, **2017**, 129, 3165-3174	2.2	82
237	Health care utilization and end-of-life care for older patients with acute myeloid leukemia. *Cancer*, **2015**, 121, 2840-8	6.4	79
236	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. *Cancer Cell*, **2015**, 28, 29-41	24.3	75
235	How I treat patients with myelodysplastic syndromes. *Blood*, **2009**, 113, 6296-303	2.2	68
234	Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. *Therapeutic Advances in Hematology*, **2019**, 10, 2040620719860645	5.7	63
233	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 877-882	3.1	58

232	Inhibition of USP10 induces degradation of oncogenic FLT3. *Nature Chemical Biology*, **2017**, 13, 1207-1215	11.7	57
231	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. *Blood*, **2017**, 129, 1763-1767	2.2	55
230	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. *Blood*, **2015**, 126, 323-323	2.2	55
229	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. *Blood*, **2020**, 135, 371-380	2.2	53
228	Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. *Journal of Clinical Oncology*, **2015**, 33, 1252-7	2.2	51
227	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. *Blood*, **2021**, 137, 1792-1803	2.2	51
226	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. *Nature Medicine*, **2017**, 23, 301-313	50.5	50
225	Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. *Science Translational Medicine*, **2018**, 10,	17.5	50
224	Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. *JAMA Oncology*, **2018**, 4, 686-693	13.4	50
223	High -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. *Blood*, **2018**, 131, 2816-2825	2.2	50
222	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. *Blood Advances*, **2020**, 4, 3528-3549	7.8	46
221	Molecular Characterization of the t(8; 13)(p11;q12) Translocation Associated With an Atypical Myeloproliferative Disorder: Evidence for Three Discrete Loci Involved in Myeloid Leukemias on 8p11. *Blood*, **1997**, 90, 3136-3141	2.2	45
220	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. *Cell Stem Cell*, **2021**, 28, 514-523.e9	18	42
219	Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 343-343	2.2	39
218	Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. *Molecular Cancer Therapeutics*, **2015**, 14, 2249-59	6.1	36
217	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1071-1071	2.2	36
216	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. *Oncologist*, **2019**, 24, 247-254	5.7	35
215	Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. *American Journal of Hematology*, **2016**, 91, 199-204	7.1	34

214	Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. *Current Opinion in Hematology*, **2017**, 24, 139-145	3.3	33
213	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 901-901	2.2	33
212	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. *Oncotarget*, **2016**, 7, 38974-38987	3.3	32
211	Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. *Leukemia and Lymphoma*, **2016**, 57, 2298-306	1.9	31
210	Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. *Blood*, **2015**, 126, 1306-1306	2.2	31
209	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. *Blood*, **2019**, 134, 867-879	2.2	29
208	Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.. *Blood*, **2005**, 106, 404-404	2.2	28
207	The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. *Hematology/Oncology Clinics of North America*, **2017**, 31, 663-680	3.1	26
206	Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. *Journal of Geriatric Oncology*, **2015**, 6, 288-98	3.6	25
205	Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. *Blood*, **2016**, 128, 1070-1070	2.2	25
204	Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. *British Journal of Haematology*, **2017**, 176, 86-91	4.5	24
203	Treatment of acute myeloid leukemia: state-of-the-art and future directions. *Seminars in Hematology*, **2002**, 39, 4-10	4	24
202	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. *Blood*, **2015**, 126, 80-80	2.2	24
201	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. *Leukemia*, **2019**, 33, 2393-2402	10.7	23
200	Acute myeloid leukemia in first remission: to choose transplantation or not?. *Journal of Clinical Oncology*, **2013**, 31, 1262-6	2.2	23
199	Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.. *Blood*, **2004**, 104, 1792-1792	2.2	23
198	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. *Blood*, **2016**, 128, 4052-4052	2.2	23
197	Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2017**, 130, 639-639	2.2	23

196	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. *Leukemia*, **2018**, 32, 2536-2545	10.7	22
195	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. *Blood*, **2019**, 134, 33-33	2.2	22
194	Novel therapeutic agents in acute myeloid leukemia. *Experimental Hematology*, **2007**, 35, 163-6	3.1	21
193	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. *Blood Advances*, **2020**, 4, 696-705	7.8	21
192	Application of multi-state models in cancer clinical trials. *Clinical Trials*, **2018**, 15, 489-498	2.2	20
191	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. *Leukemia*, **2014**, 28, 1754-1758	10.7	20
190	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. *Oncotarget*, **2017**, 8, 67639-67650	3.3	20
189	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. *Modern Pathology*, **2015**, 28, 965-76	9.8	20
188	Prognostic factors in AML in relation to (ab)normal karyotype. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 523-8	4.2	19
187	A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.. *Blood*, **2009**, 114, 755-755	2.2	19
186	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. *Blood*, **2021**, 137, 3093-3104	2.2	19
185	High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. *American Journal of Hematology*, **2019**, 94, 921-928	7.1	18
184	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. *Leukemia Research*, **2014**, 38, 430-4	2.7	18
183	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. *Blood*, **2007**, 110, 587-587	2.2	18
182	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). *Blood*, **2016**, 128, 215-215	2.2	18
181	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. *British Journal of Haematology*, **2019**, 187, 488-501	4.5	17
180	Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. *American Journal of Hematology*, **2008**, 83, 771-7	7.1	17
179	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. *Oncotarget*, **2017**, 8, 52026-52044	3.3	17

178	Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial. *Blood*, **2016**, 128, 906-906	2.2	16
177	Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. *Oncotarget*, **2016**, 7, 29131-42	3.3	16
176	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. *Lancet Haematology,the*, **2016**, 3, e276-83	14.6	16
175	Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia. *Clinical Cancer Research*, **2015**, 21, 4262-9	12.9	15
174	Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. *ACS Medicinal Chemistry Letters*, **2016**, 7, 476-81	4.3	15
173	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. *Leukemia*, **2021**, 35, 2539-2551	10.7	15
172	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. *Modern Pathology*, **2019**, 32, 1373-1385	9.8	14
171	A concise review of BCL-2 inhibition in acute myeloid leukemia. *Expert Review of Hematology*, **2018**, 11, 145-154	2.8	14
170	Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61. *Blood* **2005**, 106, 157-157	2.2	14
169	Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. *Blood*, **2015**, 126, 908-908	2.2	14
168	Simultaneous inhibition of Vps34 kinase would enhance PI3K□inhibitor cytotoxicity in the B-cell malignancies. *Oncotarget*, **2016**, 7, 53515-53525	3.3	14
167	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 3867-3867	2.2	13
166	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. *Blood Advances*, **2020**, 4, 4945-4954	7.8	13
165	Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions. *Blood*, **2019**, 134, 1326-1326	2.2	12
164	Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330). *Blood*, **2015**, 126, 258-258	2.2	12
163	Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?. *Best Practice and Research in Clinical Haematology*, **2017**, 30, 312-316	4.2	11
162	Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?. *Journal of Oncology Practice*, **2017**, 13, 471-480	3.1	11
161	Novel Therapeutics in Acute Myeloid Leukemia. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 495-503	7.1	11

160	Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. *Leukemia Research*, **2015**, 39, 204-10	2.7	11
159	Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells. *FEBS Letters*, **1991**, 294, 73-6	3.8	11
158	Optimal therapeutic strategies for mixed phenotype acute leukemia. *Current Opinion in Hematology* , **2020**, 27, 95-102	3.3	11
157	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. *Lancet Haematology,the*, **2020**, 7, e122-e133	14.6	11
156	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. *American Journal of Hematology*, **2016**, 91, 793-9	7.1	11
155	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. *Cancer Discovery*, **2021**, 11, 626-637	24.4	11
154	Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. *Leukemia Research*, **2015**, 39, 1299-1299	2.7	10
153	A Phase 1b Study of Midostaurin (PKC412) in Combination with Daunorubicin and Cytarabine Induction and High-Dose Cytarabine Consolidation in Patients Under Age 61 with Newly Diagnosed De Novo Acute Myeloid Leukemia: Overall Survival of Patients Whose Blasts Have FLT3 Mutations	2.2	10
152	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. *Blood*, **2012**, 120, 230-230	2.2	10
151	Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. *Clinical Advances in Hematology and Oncology*, **2008**, 6, 1-15	0.6	10
150	AML: New Drugs but New Challenges. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 341-350	2	9
149	Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 2968-2980	5.6	9
148	Inhibition of the deubiquitinase USP10 induces degradation of SYK. *British Journal of Cancer*, **2020**, 122, 1175-1184	8.7	9
147	Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).. *Blood*, **2006**, 108, 158-158	2.2	9
146	Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). *Blood*, **2015**, 126, 319-319	2.2	9
145	Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. *Oncotarget*, **2017**, 8, 109973-109984	3.3	9
144	What FLT3 inhibitor holds the greatest promise?. *Best Practice and Research in Clinical Haematology*, **2018**, 31, 401-404	4.2	9
143	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E49-E52	7.1	9

142	Is it time to revisit standard post-remission therapy?. *Best Practice and Research in Clinical Haematology*, **2012**, 25, 437-41	4.2	8
141	Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 3829-3829	2.2	8
140	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. *Haematologica*, **2020**, 105, 161-169	6.6	8
139	Systematic sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. *Blood Advances*, **2017**, 1, 1786-1789	7.8	7
138	Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?. *Best Practice and Research in Clinical Haematology*, **2011**, 24, 509-14	4.2	7
137	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. *Blood*, **2018**, 132, 766-766	2.2	7
136	Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1. *Blood*, **2015**, 126, 864-864	2.2	7
135	Characterization of selective and potent PI3K□inhibitor (PI3KDIN- 015) for B-Cell malignances. *Oncotarget*, **2016**, 7, 32641-51	3.3	7
134	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. *Haematologica*, **2020**, 105, 721-729	6.6	7
133	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. *Science Translational Medicine*, **2021**, 13,	17.5	6
132	Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. *Leukemia*, **2020**, 34, 625-629	10.7	6
131	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. *Cancer*, **2018**, 124, 4601-4609	6.4	6
130	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. *Cancer*, **2019**, 125, 3845-3852	6.4	5
129	Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms. *Blood*, **2020**, 136, 14-15	2.2	5
128	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. *Blood*, **2011**, 118, 258-258	2.2	5
127	DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. *Blood*, **2015**, 126, 2549-2549	2.2	5
126	Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. *Leukemia and Lymphoma*, **2020**, 61, 2900-2904	1.9	5
125	Single 6-mg dose of rasburicase: The experience in a large academic medical center. *Journal of Oncology Pharmacy Practice*, **2019**, 25, 1349-1356	1.7	5

124	Integrative omics to detect bacteremia in patients with febrile neutropenia. *PLoS ONE*, **2018**, 13, e0197049	3.7	5
123	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. *Blood*, **2020**, 136, 15-17	2.2	4
122	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms. *Blood*, **2020**, 136, 7-8	2.2	4
121	A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.. *Blood*, **2004**, 104, 873-873	2.2	4
120	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. *Blood*, **2006**, 108, 1858-1858	2.2	4
119	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. *Blood*, **2013**, 122, 2823-2823	2.2	4
118	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2597-2597	2.2	4
117	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. *Blood*, **2016**, 128, 1166-1166	2.2	4
116	Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR). *Blood*, **2016**, 128, 2859-2859	2.2	4
115	Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. *Blood*, **2016**, 128, 902-902	2.2	4
114	Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. *Blood*, **2021**, 138, 2346-2346	2.2	4
113	Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. *Nature Immunology*, **2021**, 22, 520-529	19.1	4
112	Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. *British Journal of Haematology*, **2016**, 173, 713-21	4.5	4
111	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. *Haematologica*, **2021**, 106, 1330-1342	6.6	4
110	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.. *Journal of Clinical Oncology*, **2022**, JCO2101766	2.2	4
109	3 + 7 + FLT3 inhibitors: 1 + 1 □2. *Blood*, **2017**, 129, 1061-1062	2.2	3
108	Should older adults with AML receive post-remission therapy?. *Best Practice and Research in Clinical Haematology*, **2015**, 28, 106-11	4.2	3
107	Transplantation after Remission in Mixed Phenotype Acute Leukemia: A Good Idea. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 971-972	4.7	3

106	Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 3908-3908	2.2	3
105	Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML). *Blood*, **2020**, 136, 40-41	2.2	3
104	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.. *Journal of Clinical Oncology*, **2017**, 35, 7016-7016	2.2	3
103	Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML. *Cancer Cell*, **2018**, 34, 355-357	24.3	3
102	Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. *Experimental Hematology and Oncology*, **2015**, 4, 30	7.8	2
101	Timed sequential induction chemotherapy in AML: time for reflection. *American Journal of Hematology*, **2008**, 83, 829-30	7.1	2
100	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. *Blood*, **2018**, 132, 1446-1446	2.2	2
99	Identification of Novel Splice Variants of Multiple Genes Using Genome-Wide Analysis of Alternative Splicing in Patients with Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 1278-1278	2.2	2
98	KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML. *Blood*, **2011**, 118, 2622-2622	2.2	2
97	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). *Blood*, **2012**, 120, 44-44	2.2	2
96	Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells. *Blood*, **2013**, 122, 1479-1479	2.2	2
95	BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia. *Blood*, **2013**, 122, 238-238	2.2	2
94	Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit. *Blood*, **2015**, 126, 2104-2104	2.2	2
93	Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study. *Blood*, **2015**, 126, 3306-3306	2.2	2
92	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). *Blood*, **2016**, 128, 1638-1638	2.2	2
91	A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT).. *Journal of*	2.2	2
90	A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥70 Years of Age) with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2021**, 138, 3728-3728	2.2	2
89	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. *Blood*, **2021**, 138, 639-639	2.2	2

88	Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. *Cancer*, **2020**, 126, 4735-4743	6.4	2
87	A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. *Blood Advances*, **2021**, 5, 2279-2283	7.8	2
86	The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. *Leukemia and Lymphoma*, **2016**, 57, 1977-9	1.9	2
85	Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. *Leukemia Research Reports*, **2019**, 12, 100189	0.6	2
84	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 2145-2156	5.6	1
83	Acute Myeloid Leukemia **2015**, 89-100		1
82	New agents in post-remission therapy. *Best Practice and Research in Clinical Haematology*, **2010**, 23, 475-9	4.2	1
81	Biomarker Driven Umbrella Trial of Crenolanib in Combination with Ivosidenib, Enasidenib, Venetoclax, Vyxeos and/or Salvage Chemotherapy in FLT3 Mutant AML. *Blood*, **2020**, 136, 16-17	2.2	1
80	The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment. *Blood*, **2019**, 134, 2681-2681	2.2	1
79	Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance). *Blood*, **2020**, 136, 5-7	2.2	1
78	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. *Blood*, **2006**, 108, 259-259	2.2	1
77	An Erythroid Differentiation Gene Expression Signature Predicts Response to Lenalidomide in Myelodysplasia.. *Blood*, **2006**, 108, 2668-2668	2.2	1
76	Monitoring Imatinib Resistance with a Colony Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).. *Blood*, **2006**, 108, 837-837	2.2	1
75	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. *Blood*, **2010**, 116, 848-848	2.2	1
74	The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). *Blood*, **2012**, 120, 1387-1387	2.2	1
73	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. *Blood*, **2012**, 120, 311-311	2.2	1
72	SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML). *Blood*, **2012**, 120, 773-773	2.2	1
71	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. *Blood*, **2015**, 126, 3252-3252	2.2	1

70	Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia. *Blood*, **2015**, 126, 449-449	2.2	1
69	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax. *Blood*, **2016**, 128, 4045-4045	2.2	1
68	Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation. *Blood*, **2016**, 128, 633-633	2.2	1
67	Measurement and Prevalence of Cognitive Impairment in Older Patients with Hematologic Malignancies. *Blood*, **2016**, 128, 689-689	2.2	1
66	A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).. *Journal of Clinical Oncology*, **2017**, 35, 7503-7503	2.2	1
65	Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic. *Blood*, **2021**, 138, 2291-2291	2.2	1
64	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. *Blood*, **2021**, 138, 2642-2642	2.2	1
63	Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in JAK2-mutant myeloproliferative neoplasms		1
62	Targeting MTHFD2 in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 443-443	2.2	1
61	Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. *Blood*, **2016**, 128, 2818-2818	2.2	1
60	Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. *PLoS ONE*, **2021**, 16, e0249087	3.7	1
59	Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. *American Journal of Hematology*, **2021**, 96, E259-E262	7.1	1
58	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. *Leukemia*, **2021**,	10.7	1
57	Characteristics and outcome of patients with core binding factor acute myeloid leukemia and -ITD: results from an international collaborative study. *Haematologica*, **2021**,	6.6	1
56	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. *Blood Advances*, **2021**,	7.8	1
55	PD-1 inhibition in advanced myeloproliferative neoplasms. *Blood Advances*, **2021**, 5, 5086-5097	7.8	1
54	Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 214-214	2.2	0
53	High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance). *Blood*, **2021**, 138, 221-221	2.2	0

52	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. *Blood*, **2021**, 138, 1521-1521	2.2	0
51	Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. *Blood*, **2021**, 138, 2830-2830	2.2	0
50	Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.. *Leukemia and Lymphoma*, **2022**, 1-8	1.9	0
49	Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies. *Blood*, **2020**, 136, 38-39	2.2	0
48	New Models of Therapy: When Acute Leukemia Becomes Chronic. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1856-7	4.7	
47	Myelodysplasia **2012**, 363-374		
46	Are new agents really making a difference in MDS?. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 639-46	4.2	
45	Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy. *Blood*, **2020**, 136, 40-41	2.2	
44	Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. *Blood*, **2020**, 136, 10-10	2.2	
43	Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax. *Blood*, **2021**, 138, 4126-4126	2.2	
42	Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes. *Blood*, **2021**, 138, 685-685	2.2	
41	Medical Simulation in High-Risk AML Improves Clinical Decision Making of Hematologists/Oncologists. *Blood*, **2021**, 138, 4985-4985	2.2	
40	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). *Blood*, **2021**, 138, 226-226	2.2	
39	White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance). *Blood*, **2021**, 138, 3369-3369	2.2	
38	Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912. *Blood*, **2021**, 138, 1562-1562	2.2	
37	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. *Blood*, **2004**, 104, 185-185	2.2	
36	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. *Blood*, **2004**, 104, 300-300	2.2	
35	Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.. *Blood*, **2005**, 106, 2788-2788	2.2	

34	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.. *Blood*, **2006**, 108, 1405-1405	2.2
33	High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. *Blood*, **2007**, 110, 886-886	2.2
32	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. *Blood*, **2018**, 132, 1491-1491	2.2
31	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. *Blood*, **2019**, 134, 3832-3832	2.2
30	Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols. *Blood*, **2019**, 134, 182-182	2.2
29	Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy. *Blood*, **2019**, 134, 1442-1442	2.2
28	Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells. *Blood*, **2014**, 124, 995-995	2.2
27	Identification of CKMT1B As a New Target in EVI1-Positive AML. *Blood*, **2015**, 126, 3674-3674	2.2
26	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. *Blood*, **2015**, 126, 2126-2126	2.2
25	A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2550-2550	2.2
24	Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML. *Blood*, **2015**, 126, 870-870	2.2
23	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 88-88	2.2
22	Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML. *Blood*, **2015**, 126, 326-326	2.2
21	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. *Blood*, **2015**, 126, 1138-1138	2.2
20	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. *Blood* , **2015**, 126, 1304-1304	2.2
19	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 3310-3310	2.2
18	Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia. *Blood*, **2016**, 128, 919-919	2.2
17	FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1681-1681	2.2

16	The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts). *Blood*, **2016**, 128, 287-287	2.2
15	Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia. *Blood*, **2016**, 128, 523-523	2.2
14	CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22). *Blood*, **2016**, 128, 2740-2740	2.2
13	Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia. *Blood*, **2016**, 128, 524-524	2.2
12	Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.. *Journal of Clinical Oncology*, **2017**, 35, 7004-7004	2.2
11	Prevalence and complications associated with off-label use of lenalidomide in older patients with myelodysplastic syndromes (MDS).. *Journal of Clinical Oncology*, **2017**, 35, 7054-7054	2.2
10	Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3 (GSK-3) as a Modulator of Differentiation In Acute Myeloid Leukemia. *Blood*, **2010**, 116, 1000-1000	2.2
9	Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets. *Blood*, **2011**, 118, 761-761	2.2
8	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. *Blood*, **2011**, 118, 1442-1442	2.2
7	Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors. *Blood*, **2012**, 120, 652-652	2.2
6	Geriatric Assessment Variables Add Prognostic Value to the International Prognostic Scoring System. *Blood*, **2012**, 120, 4933-4933	2.2
5	Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance). *Blood*, **2012**, 120, 1293-1293	2.2
4	Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach. *Blood*, **2013**, 122, 1378-1378	2.2
3	Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). *Blood*, **2013**, 122, 2540-2540	2.2
2	Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors. *Blood*, **2013**, 122, 3749-3749	2.2
1	Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?. *Leukemia and Lymphoma*, **2021**, 1-2	1.9